Bavarian Nordic A/S has submitted clinical data to the European Medicines Agency (EMA) to support the extension of the Imvanex (MVA-BN ) smallpox and mpox vaccine indication to… read more.
The Dengue vaccine has an efficacy rate of over 50% in reducing disease cases, with lasting effects and a very good safety profile. This is confirmed by the first global meta-analysis on the efficacy of TAK-003, better… read more.
Bavarian Nordic A/S announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a type II… read more.
GSK plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has shared 48-week findings from the PASO… read more.
New research led by Oregon Health & Science University reveals a promising approach to developing a universal influenza vaccine — a so-called “one and done” vaccine that confers… read more.
Women who receive vaccination against respiratory syncytial virus (RSV) during late pregnancy in order protect a newborn do not have an increased risk of preterm birth, researchers reported… read more.
GSK plc announced that the FDA has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50… read more.
Moderna, Inc. announced that it has submitted an application to the FDA for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1. “For four years, Moderna… read more.
Valneva SE a specialty vaccine company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion… read more.
Speaking at the World Health Assembly, authors of a new Lancet Series call for urgent global action on antimicrobial resistance (AMR), and ensuring sustainable access to antibiotics through:… read more.
Researchers at MIT, Brigham and Women’s Hospital, and Harvard Medical School have developed a potential new treatment for alopecia areata, an autoimmune disorder that causes hair loss and… read more.
The study of a novel oral vaccine that could protect against chlamydia infection has been awarded approximately $11 million in National Institutes of Health funding over five years… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
